Health Care [ 10/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
The company is headquartered in Doylestown, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | -0.53 Increased by +8.62% | -0.71 Increased by +25.35% |
| May 12, 25 | -0.66 Increased by +2.07% | -1.00 Increased by +34.39% |
| Mar 25, 25 | -0.49 Increased by +46.74% | -0.54 Increased by +9.26% |
| Nov 7, 24 | -0.64 Increased by +25.58% | -0.74 Increased by +13.51% |
| Aug 12, 24 | -0.58 Increased by +33.33% | -0.63 Increased by +7.94% |
| May 14, 24 | -0.67 Increased by +50.00% | -0.78 Increased by +14.10% |
| Mar 26, 24 | -0.92 Increased by 0.00% | -0.77 Decreased by -19.48% |
| Nov 9, 23 | -0.86 Increased by +64.17% | -1.16 Increased by +25.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 118.11 K Decreased by -78.97% | -3.24 M Increased by +6.66% | Decreased by -2.74 K% Decreased by -343.79% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -3.93 M Decreased by -39.95% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 205.82 K Increased by +1.36 K% | -2.89 M Increased by +15.93% | Decreased by -1.41 K% Increased by +94.25% |
| Sep 30, 24 | 354.62 K Increased by +11.00% | -3.78 M Decreased by -18.08% | Decreased by -1.07 K% Decreased by -6.37% |
| Jun 30, 24 | 561.57 K Increased by +124.91% | -3.47 M Decreased by -6.47% | Decreased by -617.92% Increased by +52.66% |
| Mar 31, 24 | 380.57 K Increased by +N/A% | -2.81 M Increased by +32.30% | Decreased by -738.39% Decreased by N/A% |
| Dec 31, 23 | 14.07 K Increased by +N/A% | -3.44 M Increased by +96.89% | Decreased by -24.46 K% Decreased by N/A% |
| Sep 30, 23 | 319.47 K Increased by +N/A% | -3.20 M Increased by +23.26% | Decreased by -1.00 K% Decreased by N/A% |